Adaptive Biotechnologies Corporation (ADPT)Healthcare | Biotechnology | Seattle, United States | NasdaqGS
14.47 USD
+0.39
(2.770%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 14.53 +0.06 (0.428%) ⇧ (April 17, 2026, 5:48 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:41 p.m. EDT
ADPT is a 'Buy and Hope' high-beta biotech play driven by robust revenue growth (51% YoY) and analyst optimism, selling near its 3-year high despite negative profitability. The fundamental risk is a value trap with no earnings replay multiple, making the valuation (P/S of 8.0) entirely speculative. Short-term momentum is supported by call flow targeting upside, but the lack of free cash flow and negative operating margins necessitates patience unless a major catalyst closes the earnings gap. Current price action shows volatility around the 14.00-15.00 resistance zone, with limited short-term downside support based on options flow. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.243359 |
| MSTL | 0.253335 |
| AutoTheta | 0.293372 |
| AutoARIMA | 0.308048 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 51% |
| H-stat | 3.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.476 |
| Excess Kurtosis | -0.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 93.491 |
| Revenue per Share | 1.826 |
| Market Cap | 2,228,113,408 |
| Forward P/E | -53.88 |
| Beta | 2.30 |
| Profit Margins | -21.48% |
| Website | https://www.adaptivebiotech.com |
As of April 18, 2026, 11:41 p.m. EDT: Speculative positioning is heavily skewed towards calls (Upside bias). Call Open Interest peaks significantly at strikes above the current price (15.0 and 20.0), suggesting break-even targets 1-3 months out. Conversely, Put Open Interest is flat, with zero volume reported for key strikes in the near term (May), indicating a lack of organized downside hedging. Implied Volatility is elevated for puts (8.39 ATM vs 0.83 for calls in May), offering potential value but reflecting fear premiums at far OTM strikes, while call activity is concentrated in OTM territory. The skew suggests a narrative focused on earnings-driven rallies rather than downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1185944 |
| Address1 | 1,165 Eastlake Avenue East |
| All Time High | 71.25 |
| All Time Low | 2.28 |
| Ask | 14.56 |
| Ask Size | 16 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,842,360 |
| Average Daily Volume3 Month | 2,009,787 |
| Average Volume | 2,009,787 |
| Average Volume10Days | 1,842,360 |
| Beta | 2.296 |
| Bid | 14.35 |
| Bid Size | 16 |
| Board Risk | 8 |
| Book Value | 1.423 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.47 |
| Current Ratio | 3.339 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 14.91 |
| Day Low | 14.385 |
| Debt To Equity | 93.491 |
| Display Name | Adaptive Biotechnologies |
| Earnings Call Timestamp End | 1,778,013,000 |
| Earnings Call Timestamp Start | 1,778,013,000 |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -39,290,000 |
| Ebitda Margins | -0.14185001 |
| Enterprise To Ebitda | -56.444 |
| Enterprise To Revenue | 8.007 |
| Enterprise Value | 2,217,697,280 |
| Eps Current Year | -0.48 |
| Eps Forward | -0.26857 |
| Eps Trailing Twelve Months | -0.39 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 206 659 0667 |
| Fifty Day Average | 14.688 |
| Fifty Day Average Change | -0.21799946 |
| Fifty Day Average Change Percent | -0.014842011 |
| Fifty Two Week Change Percent | 111.85944 |
| Fifty Two Week High | 20.76 |
| Fifty Two Week High Change | -6.29 |
| Fifty Two Week High Change Percent | -0.3029865 |
| Fifty Two Week Low | 6.775 |
| Fifty Two Week Low Change | 7.695 |
| Fifty Two Week Low Change Percent | 1.1357933 |
| Fifty Two Week Range | 6.775 - 20.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,561,642,200,000 |
| Float Shares | 118,709,005 |
| Forward Eps | -0.26857 |
| Forward P E | -53.877945 |
| Free Cashflow | 950,875 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 624 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.74236 |
| Gross Profits | 205,616,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02024 |
| Held Percent Institutions | 0.99594 |
| Implied Shares Outstanding | 153,981,561 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. |
| Long Name | Adaptive Biotechnologies Corporation |
| Market | us_market |
| Market Cap | 2,228,113,408 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_100147173 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -59,499,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,229,653,003 |
| Number Of Analyst Opinions | 7 |
| Open | 14.55 |
| Operating Cashflow | -45,986,000 |
| Operating Margins | -0.17819001 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 206 659 0067 |
| Post Market Change | 0.06199932 |
| Post Market Change Percent | 0.428468 |
| Post Market Price | 14.532 |
| Post Market Time | 1,776,462,489 |
| Previous Close | 14.08 |
| Price Eps Current Year | -30.145834 |
| Price Hint | 2 |
| Price To Book | 10.168658 |
| Price To Sales Trailing12 Months | 8.044428 |
| Profit Margins | -0.21482 |
| Quick Ratio | 3.101 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.39 |
| Regular Market Change Percent | 2.76989 |
| Regular Market Day High | 14.91 |
| Regular Market Day Low | 14.385 |
| Regular Market Day Range | 14.385 - 14.91 |
| Regular Market Open | 14.55 |
| Regular Market Previous Close | 14.08 |
| Regular Market Price | 14.47 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,565,687 |
| Return On Assets | -0.06787 |
| Return On Equity | -0.27817 |
| Revenue Growth | 0.51 |
| Revenue Per Share | 1.826 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 153,981,561 |
| Shares Percent Shares Out | 0.0556 |
| Shares Short | 8,558,955 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,877,604 |
| Short Name | Adaptive Biotechnologies Corpor |
| Short Percent Of Float | 0.071 |
| Short Ratio | 3.66 |
| Source Interval | 15 |
| State | WA |
| Symbol | ADPT |
| Target High Price | 22.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 20.57143 |
| Target Median Price | 21.0 |
| Total Cash | 226,980,000 |
| Total Cash Per Share | 1.474 |
| Total Debt | 210,356,000 |
| Total Revenue | 276,976,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.774075 |
| Two Hundred Day Average Change | -0.3040743 |
| Two Hundred Day Average Change Percent | -0.020581612 |
| Type Disp | Equity |
| Volume | 1,565,687 |
| Website | https://www.adaptivebiotech.com |
| Zip | 98,109 |